Gynecologic Oncology

Papers
(The H4-Index of Gynecologic Oncology is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Editorial board120
Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study86
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies85
Corrigendum to “Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC) 81
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials76
Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement69
Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study65
Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage62
The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study62
Uterine cancer incidence overtakes colorectal cancer, disproportionately impacting minority women in the United States59
Molecular testing in the upfront setting for high-grade endometrial cancer: How are we doing?58
Quantifying opportunities to reduce high-grade serous ovarian cancer via opportunistic salpingectomy58
Ovarian-Adnexal Reporting and Data System (O-RADS) for adnexal masses: Are we hitting the mark?57
Investigating the role of the poly (ADP-ribose) polymerase enzyme family in cervical cancer pathogenesis55
Combination of BVAC-C and durvalumab in recurrent or metastatic cervical cancer: A phase II study52
Obesity and ovarian cancer: Leveraging real-world data for incidence and outcomes using a multicenter nationwide electronic database52
A phase I, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (Claudin 6 x CD3) T-cell engaging bispecific antibody in advanced solid tumors51
Trends in FDA approval of novel therapies in women's cancer: A study of the last 25 years50
Clear cell carcinoma of cervix and vagina: A review of 63 cases in the post-diethylstilbestrol era49
(ENCORE) Long-term safety and efficacy of selinexor maintenance treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-30549
2025 Annual Meeting on Women's Cancer – SGO Meeting Insights48
Endometrial cancer survivors' perceptions of their cardiovascular disease risk (results from WF-1804CD AH-HA)47
Prognosis of patients who become pregnant after achieving a complete response with fertility-sparing treatment in early endometrial cancer: A Gynecologic Oncology Research Investigators Collaboration 47
Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor46
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer – An NRG/GOG study46
Profiling the immune landscape in mucinous ovarian carcinoma46
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA12544
ChatGPT vs Google: Understanding a patient's perspective on their cancer diagnosis, recommended treatment, and survival outcomes41
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer41
Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices41
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial41
Racial disparities in human papillomavirus vaccination rates and correlation with cervical cancer stage at diagnosis: A retrospective analysis41
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer39
Endometrial stripe thickness at the time of diagnosis of uterine papillary serous carcinoma in black patients (2137)38
Prediction of ovarian cancer with deep machine-learning and alternative splicing (2167)37
Liquid biopsy for advanced endometrial cancer: Prognostic value of plasma circulating DNA fraction in real-world settings (1320)36
The impact of bowel preparation on surgical site infection rates in gynecologic oncology surgery, post-hoc analysis from a randomized controlled trial (550)36
Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)36
Short-term hormone replacement therapy in BRCA mutation carriers and risk of breast cancer: A nationwide study in Korea (1155)36
0.60682392120361